ScienceDaily (June 4, 2008) — Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.

Rickets is a softening of the bones that most commonly results from a lack of vitamin D or calcium and from insufficient exposure to sunlight. Hypophosphatasia is a rare, heritable form of rickets caused by mutations in a gene called TNAP, which is essential for the process that causes minerals such as calcium and phosphorus to be deposited in developing bones and teeth. The physical presentations of this disorder can vary depending on the specific mutation, with more severe symptoms occurring at a younger age of onset. The most severe form of the disease occurs at birth, which can present with absence of bone mineralization in utero, resulting in stillbirth.

Using a mouse model, José Luis Millán, Ph.D. tested the hypothesis that, when administered from birth, a bone-targeted form of the TNAP gene would ease the skeletal defects of HPP. The Millán laboratory, in collaboration with scientists from Enobia Pharma in Montreal, Canada and from the Shriners Hospitals for Children in St. Louis, Missouri, created a soluble form of human TNAP that had been shown to display a strong attraction to bone tissue. Upon injecting the enzyme into the fat layer under the skin of the mice, the treated mice maintained a healthy rate of growth and apparent well being, as well as normal bone mineral density (BMD) of the skull, femur and spine. In fact, complete preservation of skeletal and dental structures were observed after 15 days, and bone lesions were still not seen after 52 days of treatment.

"While the biochemical mechanism that leads to skeletal and dental defects of HPP is now generally understood," said Dr. Millán, "there is currently no established medical treatment."

Given the success of this therapy in preventing HPP, current efforts in Dr. Millán's laboratory are focused on reversing the bone defects in mice once the disease is quite advanced. Future clinical trials may reveal this as the first promising therapy for patients with this genetic disorder.

This study, published in the Journal of Bone and Mineral Research, was supported by grants from the National Institutes of Health, Enobia Pharma, Inc., and the Shriners Hospitals for Children.

Related Stories

Treatment Discovered For Deadly Childhood Disease (Dec. 11, 2006) — Researchers have discovered that a treatment involving enzyme replacement therapy dramatically reduces the risk of death in children with Pompe disease, a rare genetic disorder in which most children ...  > read more

Research Holds Promise For Novel Oral Anti-diabetic Drugs (June 14, 2009) — Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a Hebrew University of Jerusalem ...  > read more

New Therapy May Mean Less Dietary Restrictions For Celiac Sufferers (June 24, 2006) — Scientists have discovered what may be a successful non-dietary therapy for celiac sprue, an inherited inflammatory disorder of the small intestine that impacts an estimated 1 in 200 people around ...  > read more

Replacing The Cells Lost In Parkinson Disease (Dec. 5, 2007) — Parkinson disease is caused by the progressive degeneration of dopamine brain cells. Replacing these cells is considered a promising therapeutic strategy. Although DA cell--replacement therapy by ...  > read more

Eight-year Clinical Outcomes Of Enzyme Replacement Therapy In 884 Children With Type I Gaucher Disease (Nov. 16, 2008) — Gaucher disease is a rare genetic disorder that occurs when a person lacks an enzyme called glucocerebrosidase. The most common form of this disorder is type 1 Gaucher disease. Type 1 Gaucher disease ...  > read more

Search ScienceDaily

Patients Go Wireless For Faster Recovery